Unnamed: 0,title,date,stock,sentiment
788690.0,Lexicon Pharma Highlights Will Present Preclinical Efficacy Data On Telotristat Ethyl's Antiproliferative Effects Against Various Cancer Cell Lines,2020-05-13 18:01:00-04:00,LXRX,negative
788691.0,"Citigroup Maintains Neutral on Lexicon Pharmaceuticals, Lowers Price Target to $2.1",2020-04-28 08:40:00-04:00,LXRX,negative
788692.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,LXRX,neutral
788693.0,72 Stocks Moving In Monday's Mid-Day Session,2020-04-27 12:34:00-04:00,LXRX,neutral
788694.0,Lexicon Pharmaceuticals shares higher after the company reported better-than-expected Q1 EPS and sales results.,2020-04-27 08:48:00-04:00,LXRX,positive
788695.0,Lexicon Pharmaceuticals: Q1 Earnings Insights,2020-04-27 07:43:00-04:00,LXRX,neutral
788696.0,"Lexicon Pharmaceuticals Q1 EPS $(0.63) Beats $(0.69) Estimate, Sales $7.999M Beat $7.790M Estimate",2020-04-27 07:02:00-04:00,LXRX,neutral
788697.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,LXRX,negative
788698.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,LXRX,negative
788699.0,Lexicon Pharmaceuticals To Close Out Early Two Long-Term Outcome Studies Of Sotagliflozin Based On 'assessment that a near-term partnership sufficient to fund the studies to completion is now unlikely' As Well As Coronavirus Uncertainty,2020-03-19 16:03:00-04:00,LXRX,negative
788700.0,Lexicon Pharma Reports Added Data On Telotristat Ethyl's Antiproliferative Effects In Patients With Carcinoid Syndrome,2020-03-13 08:22:00-04:00,LXRX,neutral
788701.0,Lexicon Pharmaceuticals: Q4 Earnings Insights,2020-03-12 13:40:00-04:00,LXRX,neutral
788702.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,LXRX,negative
788703.0,"Lexicon Pharmaceuticals Q4 EPS $(0.48) Beats $(0.77) Estimate, Sales $8.727M Miss $10.26M Estimate",2020-03-12 07:11:00-04:00,LXRX,negative
788704.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,LXRX,negative
788705.0,15 Biotechnology Stocks Moving In Thursday's After-Market Session,2020-01-23 23:28:00-05:00,LXRX,neutral
788706.0,20 Healthcare Stocks Moving In Thursday's After-Market Session,2020-01-23 23:13:00-05:00,LXRX,neutral
788707.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,LXRX,neutral
788708.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,LXRX,neutral
788709.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,LXRX,neutral
788710.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,LXRX,neutral
788711.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,LXRX,neutral
788712.0,Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium,2020-01-20 18:01:00-05:00,LXRX,neutral
788713.0,"Lexicon Pharma 8-K Shows Co.'s Lex-Gen Woodlands Subsidiary Agreed To Sell Facilities In The Woodlands, Texas For $15M",2020-01-16 16:15:00-05:00,LXRX,positive
788714.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-20 08:19:00-05:00,LXRX,neutral
788715.0,Lexicon Pharma Reports Topline Phase 3 Data For Sotagliflozin In Type 2 Diabetes: Met Primary Endpoint,2019-12-20 07:03:00-05:00,LXRX,neutral
788716.0,"Benzinga's Top Upgrades, Downgrades For December 11, 2019",2019-12-11 10:46:00-05:00,LXRX,positive
788717.0,Gabelli & Co. Downgrades Lexicon Pharmaceuticals to Hold,2019-12-11 08:35:00-05:00,LXRX,neutral
788718.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,LXRX,neutral
788719.0,55 Stocks Moving In Friday's Mid-Day Session,2019-12-06 12:02:00-05:00,LXRX,neutral
788720.0,Lexicon Pharmaceuticals shares are trading higher on continued momentum after the company reported the topline Phase 1 data for its LX9211. NOTE: The study showed favorable safety results.,2019-12-06 10:33:00-05:00,LXRX,positive
788721.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,LXRX,neutral
788722.0,Lexicon Pharmaceuticals shares are trading higher after the company reported the topline Phase 1 data for its LX9211. NOTE: The study showed favorable safety results.,2019-12-05 14:35:00-05:00,LXRX,positive
788723.0,"Lexicon Pharma Reports Topline Phase 1 Data For LX9211: Shows Favorable Safety, Pharmacokinetics Profile Supportive Of Once-Daily Dosing",2019-12-05 07:25:00-05:00,LXRX,positive
788724.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,LXRX,neutral
788725.0,Lexicon Pharmaceuticals shares are trading higher on continued momentum after the company announced it completed the initial stage for its Phase 2 clinical study of TELE-ABC.,2019-12-04 14:07:00-05:00,LXRX,positive
788726.0,Lexicon Pharmaceuticals Completes Safety Review Of Initial Safety Run-In Cohort Of TELE-ABC Phase 2 Clinical Study Of Telotristat Ethyl In Biliary Tract Cancer,2019-12-03 07:11:00-05:00,LXRX,positive
788727.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,LXRX,neutral
788728.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-02 12:11:00-05:00,LXRX,neutral
788729.0,Why Lexicon Pharma Shares Are Moving Lower,2019-12-02 11:09:00-05:00,LXRX,neutral
788730.0,Lexicon Pharmaceuticals shares are trading lower after the FDA reiterated its prior decision and denied Lexicon's appeal of the complete response letter for its Sotagliflozin.,2019-12-02 08:20:00-05:00,LXRX,negative
788731.0,Lexicon Pharma's Appeal of the FDA's Complete Response Letter for Sotagliflozin is Denied,2019-12-02 07:06:00-05:00,LXRX,negative
788732.0,Lexicon Pharmaceuticals shares are trading higher. Not currently seeing any company-specific news.,2019-11-20 11:43:00-05:00,LXRX,positive
788733.0,"Benzinga's Top Upgrades, Downgrades For November 8, 2019",2019-11-08 09:33:00-05:00,LXRX,positive
788734.0,Lexicon Pharmaceuticals shares are trading lower after Citigroup downgraded the stock from Buy to Neutral.,2019-11-08 09:00:00-05:00,LXRX,neutral
788735.0,"Citigroup Downgrades Lexicon Pharmaceuticals to Neutral, Raises Price Target to $4",2019-11-08 07:13:00-05:00,LXRX,neutral
788736.0,Lexicon Pharma Filing Shows Registration For $150M Mixed Securities Offering,2019-11-07 16:39:00-05:00,LXRX,positive
788737.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-07 08:04:00-05:00,LXRX,neutral
788738.0,30 Stocks Moving in Thursday's Pre-Market Session,2019-11-07 07:58:00-05:00,LXRX,neutral
788739.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,LXRX,negative
788740.0,"Lexicon Pharmaceuticals Q3 EPS $1.95 vs $0.73 Estimate, Sales $294.448M Up From $6.856M YoY",2019-11-07 07:11:00-05:00,LXRX,neutral
788741.0,Lexicon Pharmaceuticals shares are trading higher in sympathy with the overall market on optimism around the U.S.-China trade deal.,2019-10-25 12:49:00-04:00,LXRX,positive
788742.0,Lexicon Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-10-07 11:46:00-04:00,LXRX,positive
788743.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,LXRX,neutral
788744.0,31 Stocks Moving In Monday's Mid-Day Session,2019-09-30 13:13:00-04:00,LXRX,neutral
788745.0,"Lexicon Pharmaceuticals shares are trading lower, potentially following a bearish blog post alleging the company does not have enough cash to finish ongoing trials.",2019-09-30 10:12:00-04:00,LXRX,neutral
788746.0,18 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-09-30 08:44:00-04:00,LXRX,neutral
788747.0,55 Biggest Movers From Yesterday,2019-09-26 04:34:00-04:00,LXRX,neutral
788748.0,Lexicon Pharmaceuticals shares are trading higher. The stock appears to be rebounding following a potential sell-off. Not seeing any news to justify the price action,2019-09-25 15:18:00-04:00,LXRX,positive
788749.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tue., September 24, 2019",2019-09-24 14:03:00-04:00,LXRX,positive
788750.0,Lexicon Pharmaceuticals shares are trading lower. This could potentially be profit taking from investors after the stock rallied approximately 123% over the past 30 days.,2019-09-24 12:13:00-04:00,LXRX,positive
788751.0,15 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-20 08:24:00-04:00,LXRX,neutral
788752.0,46 Biggest Movers From Yesterday,2019-09-20 04:45:00-04:00,LXRX,neutral
788753.0,32 Stocks Moving In Thursday's Mid-Day Session,2019-09-19 12:54:00-04:00,LXRX,neutral
788754.0,Lexicon Pharmaceuticals shares are trading lower as traders potentially took profits after the stock increased roughly 50% since last week.,2019-09-19 09:44:00-04:00,LXRX,positive
788755.0,18 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-19 08:19:00-04:00,LXRX,neutral
788756.0,52 Biggest Movers From Yesterday,2019-09-19 05:18:00-04:00,LXRX,neutral
788757.0,Mid-Afternoon Market Update: Dow Falls Over 200 Points After Federal Reserve Lowers Interest Rates,2019-09-18 14:48:00-04:00,LXRX,positive
788758.0,36 Stocks Moving In Wednesday's Mid-Day Session,2019-09-18 13:19:00-04:00,LXRX,neutral
788759.0,Mid-Day Market Update: FedEx Falls Following Downbeat Q2 Results; SPI Energy Shares Jump,2019-09-18 12:20:00-04:00,LXRX,positive
788760.0,Mid-Morning Market Update: Markets Edge Lower; General Mills Posts Mixed Q1 Results,2019-09-18 10:46:00-04:00,LXRX,negative
788761.0,"Lexicon Pharmaceuticals shares are trading higher after two company insiders bought shares totaling $1.054 million. NOTE: When an insiders buy shares, the market may perceive it as a sign of confidence in the company's outlook.",2019-09-18 09:49:00-04:00,LXRX,positive
788762.0,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,2019-09-17 16:35:00-04:00,LXRX,neutral
788763.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tuesday, September 17, 2019",2019-09-17 12:20:00-04:00,LXRX,positive
788764.0,Lexicon Pharmaceuticals shares are are trading higher on continued momentum from Thursday when the company gave insight into the cash it will receive for its Zynquista Diabetes Program. The stock has increased roughly 30% since the announcement.,2019-09-17 11:22:00-04:00,LXRX,positive
788765.0,"The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study",2019-09-17 07:23:00-04:00,LXRX,neutral
788766.0,Lexicon Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-09-16 14:07:00-04:00,LXRX,neutral
788767.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,LXRX,positive
788768.0,24 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-13 08:44:00-04:00,LXRX,neutral
788769.0,58 Biggest Movers From Yesterday,2019-09-13 07:04:00-04:00,LXRX,neutral
788770.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-12 08:36:00-04:00,LXRX,neutral
788771.0,33 Stocks Moving in Thursday's Pre-Market Session,2019-09-12 07:59:00-04:00,LXRX,neutral
788772.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,LXRX,neutral
788773.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; Zscaler Shares Tumble On Weak Earnings Guidance,2019-09-11 14:38:00-04:00,LXRX,negative
788774.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-09-11 12:27:00-04:00,LXRX,neutral
788775.0,Mid-Day Market Update: Crude Oil Down Over 2%; T2 Biosystems Shares Spike Higher,2019-09-11 12:13:00-04:00,LXRX,negative
788776.0,"Benzinga's Top Upgrades, Downgrades For September 11, 2019",2019-09-11 10:31:00-04:00,LXRX,positive
788777.0,Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Buy,2019-09-11 08:34:00-04:00,LXRX,neutral
788778.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-11 08:21:00-04:00,LXRX,neutral
788779.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-09-11 07:59:00-04:00,LXRX,neutral
788780.0,Lexicon Pharmaceuticals shares are trading higher after the company announced the termination of its alliance and settlement with Sanofi. Sanofi must pay the company $260 million.,2019-09-11 07:34:00-04:00,LXRX,positive
788781.0,"The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway",2019-09-11 07:09:00-04:00,LXRX,neutral
788782.0,"Lexicon Pharma Shares Resume Trade, Up 35.5%",2019-09-10 16:35:00-04:00,LXRX,positive
788783.0,Lexicon Pharmaceuticals shares are trading higher after the company announced the termination of its alliance and settlement with Sanofi. Sanofi must pay the company $260 million.,2019-09-10 16:06:00-04:00,LXRX,positive
788784.0,Lexicon Pharmaceuticals Announces Termination Of Alliance and Settlement With Sanofi; Sanofi To Pay Co. $206M,2019-09-10 16:02:00-04:00,LXRX,negative
788785.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-08-21 08:48:00-04:00,LXRX,neutral
788786.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Tue., August 13, 2019",2019-08-13 12:56:00-04:00,LXRX,positive
788787.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., August 12, 2019",2019-08-12 12:55:00-04:00,LXRX,positive
788788.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., August 09, 2019",2019-08-09 12:53:00-04:00,LXRX,positive
788789.0,Lexicon Pharmaceuticals shares are trading higher after the company announced positive cardiorenal results from a pooled analysis from the inTandem1 and inTandem2 studies of Zynquista in adults with type 1 diabetes.,2019-08-09 11:41:00-04:00,LXRX,positive
788790.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,LXRX,neutral
788791.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,LXRX,neutral
788792.0,Lexicon Pharma Highlights Publication Of Data For Zynquista On Cardiorenal Clinical Biomarkers In Adults With Type 1 Diabetes,2019-08-08 17:30:00-04:00,LXRX,neutral
788793.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,LXRX,neutral
788794.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., August 7, 2019",2019-08-07 12:50:00-04:00,LXRX,positive
788795.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,LXRX,neutral
788796.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,LXRX,neutral
788797.0,29 Healthcare Stocks Moving In Friday's After-Market Session,2019-08-02 20:51:00-04:00,LXRX,neutral
788798.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019",2019-08-02 14:03:00-04:00,LXRX,positive
788799.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,LXRX,negative
788800.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,LXRX,negative
788801.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,LXRX,negative
788802.0,New 52-Week Low Achievers For Wednesday Morning,2019-07-31 11:16:00-04:00,LXRX,negative
788803.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-31 09:41:00-04:00,LXRX,neutral
788804.0,"Lexicon Pharmaceuticals Q2 EPS $(0.22) Misses $(0.08) Estimate, Sales $9.7M Do Not Compare To $28.52M Estimate",2019-07-31 07:11:00-04:00,LXRX,negative
788805.0,28 Healthcare Stocks Moving In Tuesday's After-Market Session,2019-07-31 04:01:00-04:00,LXRX,neutral
788806.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tue., July 30, 2019",2019-07-30 13:37:00-04:00,LXRX,positive
788807.0,10 Biggest Price Target Changes For Tuesday,2019-07-30 09:13:00-04:00,LXRX,neutral
788808.0,"Citigroup Maintains Buy on Lexicon Pharmaceuticals, Lowers Price Target to $3",2019-07-30 07:55:00-04:00,LXRX,negative
788809.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,LXRX,positive
788810.0,54 Biggest Movers From Yesterday,2019-07-30 05:00:00-04:00,LXRX,neutral
788811.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Lexicon Pharmaceuticals Shares Plunge,2019-07-29 14:22:00-04:00,LXRX,negative
788812.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-29 12:30:00-04:00,LXRX,neutral
788813.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., July 29, 2019",2019-07-29 12:24:00-04:00,LXRX,positive
788814.0,Mid-Day Market Update: On Deck Capital Falls On Downbeat Earnings; Medley Management Shares Jump,2019-07-29 12:13:00-04:00,LXRX,positive
788815.0,"Mid-Morning Market Update: Markets Mostly Lower; Mylan, Pfizer's Upjohn To Merge",2019-07-29 10:16:00-04:00,LXRX,negative
788816.0,"UPDATE: Stifel Downgrades Lexicon Pharmaceuticals To Hold, Lowers Target To $4 As Firm Notes 'Sanofi's Planned Sotagliflozin Exodus & P3 T2D CKD Data Clouds Visibility & Thesis'",2019-07-29 10:16:00-04:00,LXRX,negative
788817.0,What Caused The Opening Gap In Lexicon?,2019-07-29 10:00:00-04:00,LXRX,neutral
788818.0,"Benzinga's Top Upgrades, Downgrades For July 29, 2019",2019-07-29 09:55:00-04:00,LXRX,positive
788819.0,30 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-29 09:35:00-04:00,LXRX,neutral
788820.0,10 Biggest Price Target Changes For Monday,2019-07-29 09:08:00-04:00,LXRX,neutral
788821.0,35 Stocks Moving In Monday's Pre-Market Session,2019-07-29 08:30:00-04:00,LXRX,neutral
788822.0,Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi,2019-07-29 08:10:00-04:00,LXRX,positive
788823.0,Lexicon Pharmaceuticals shares are trading lower after Sanofi terminated its Zynquista collaboration with the company.,2019-07-29 07:39:00-04:00,LXRX,neutral
788824.0,Lexicon Shares Fall 52% on Termination of License Agreement with Sanofi,2019-07-29 07:05:00-04:00,LXRX,positive
788825.0,Lexicon Pharmaceuticals Received Written Notice from Sanofi Terminating the Collaboration and License Agreement for the Worldwide Development and Commercialization of the Company's Diabetes Drug Candidate Sotagliflozin,2019-07-29 07:04:00-04:00,LXRX,positive
788826.0,"Stifel Nicolaus Downgrades Lexicon Pharmaceuticals to Hold, Lowers Price Target to $4",2019-07-29 06:57:00-04:00,LXRX,negative
788827.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,LXRX,neutral
788828.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,LXRX,negative
788829.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,LXRX,neutral
788830.0,38 Stocks Moving In Monday's Mid-Day Session,2019-04-29 12:36:00-04:00,LXRX,neutral
788831.0,Lexicon Pharmaceuticals shares are trading higher after the company disclosed that Zynquista was approved in the European Union for the treatment of adults with Type 1 diabetes.,2019-04-29 08:42:00-04:00,LXRX,positive
788832.0,22 Stocks Moving In Monday's Pre-Market Session,2019-04-29 08:00:00-04:00,LXRX,neutral
788833.0,A Peek Into The Markets: US Stock Futures Edge Lower; Alphabet Earnings In Focus,2019-04-29 07:23:00-04:00,LXRX,negative
788834.0,"8 Stocks To Watch For April 29, 2019",2019-04-29 05:00:00-04:00,LXRX,neutral
788835.0,Lexicon Pharmaceuticals shares are trading higher after the company's Zynquista was approved in the European Union for the treatment of adults with Type 1 diabetes.,2019-04-26 16:08:00-04:00,LXRX,positive
788836.0,Sanofi And Lexicon Zynquista Now Approved In The European Union For Treatment Of Adults With Type 1 Diabetes,2019-04-26 16:01:00-04:00,LXRX,positive
788837.0,52 Biggest Movers From Yesterday,2019-03-26 05:04:00-04:00,LXRX,neutral
788838.0,41 Stocks Moving In Monday's Mid-Day Session,2019-03-25 12:51:00-04:00,LXRX,neutral
788839.0,Gabelli & Co. Upgrades Lexicon Pharmaceuticals to Hold,2019-03-25 09:57:00-04:00,LXRX,neutral
788840.0,60 Biggest Movers From Friday,2019-03-25 05:42:00-04:00,LXRX,neutral
788841.0,"Lexicon Pharmaceuticals shares are trading lower after the FDA issued a complete response letter to the company, informing it that the application for its Zynquista type 1 diabetes treatment cannot be approved in its current form.",2019-03-22 15:26:00-04:00,LXRX,negative
788842.0,"Lexicon Pharma Halted Multiple Times on Volatility Following Announcement of CRL from FDA. Now at $5.63, $1.38 Off the Low",2019-03-22 15:06:00-04:00,LXRX,negative
788843.0,"Lexicon Shares Resumed Trade, Immediately Halted On Circuit Breaker, Down 40%",2019-03-22 14:59:00-04:00,LXRX,positive
788844.0,Lexicon Pharmaceuticals Resumes Trade after Announcing CRL and Immediately Halted on a Circuit Breaker,2019-03-22 14:46:00-04:00,LXRX,neutral
788845.0,"Lexicon Pharma Shares Resume Trade, Down 41%",2019-03-22 14:45:00-04:00,LXRX,positive
788846.0,Lexicon Shares To Resume Trade At 2:45 p.m. EDT,2019-03-22 14:21:00-04:00,LXRX,positive
788847.0,Lexicon Reports FDA Issued Complete Response Letter For Zynquista,2019-03-22 14:16:00-04:00,LXRX,neutral
788848.0,"Lexicon Pharma Shares Were Halted For News Pending About 70 Mins Ago; Stock Remains Halted Ahead Of Expected FDA Verdict On Diabetes Candidate, Zynquista",2019-03-22 13:51:00-04:00,LXRX,positive
788849.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-03-16 08:35:00-04:00,LXRX,neutral
788850.0,"Lexicon Pharmaceuticals Announces Dosing Of First Patient In TELE-ABC Study, A Phase 2a Clinical Study Of Telotristat Ethyl In Biliary Tract Cancer",2019-03-15 10:40:00-04:00,LXRX,negative
788851.0,"Benzinga's Top Upgrades, Downgrades For March 14, 2019",2019-03-14 09:20:00-04:00,LXRX,positive
788852.0,Gabelli & Co. Downgrades Lexicon Pharmaceuticals to Sell,2019-03-14 08:25:00-04:00,LXRX,neutral
788853.0,68 Biggest Movers From Yesterday,2019-03-14 05:22:00-04:00,LXRX,neutral
788854.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-03-13 12:41:00-04:00,LXRX,neutral
788855.0,Lexicon Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,2019-03-13 09:51:00-04:00,LXRX,positive
788856.0,40 Stocks Moving In Wednesday's Pre-Market Session,2019-03-13 08:10:00-04:00,LXRX,neutral
788857.0,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",2019-03-13 07:27:00-04:00,LXRX,negative
788858.0,"Lexicon Pharmaceuticals Q4 EPS $(0.16) Beats $(0.29) Estimate, Sales $17.1M Beat $13.33M Estimate",2019-03-13 07:02:00-04:00,LXRX,neutral
788859.0,"Earnings Scheduled For March 13, 2019",2019-03-13 05:17:00-04:00,LXRX,neutral
788860.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,LXRX,neutral
788861.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,LXRX,neutral
788862.0,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Nutanix Shares Plunge On Weak Forecast,2019-03-01 14:31:00-05:00,LXRX,negative
788863.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,LXRX,neutral
788864.0,Shares of Lexicon Pharmaceuticals are trading higher after the CHMP recommended the company's Zynquista for the treatment of adults with type 1 diabetes.,2019-03-01 09:20:00-05:00,LXRX,positive
788865.0,CHMP Recommends Lexicon And Sanofi's Zynquista For The Treatment Of Adults With Type 1 Diabetes,2019-03-01 08:01:00-05:00,LXRX,positive
788866.0,"The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug",2019-01-25 07:38:00-05:00,LXRX,positive
788867.0,"Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019",2019-01-24 10:05:00-05:00,LXRX,negative
788868.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,LXRX,negative
788869.0,54 Biggest Movers From Yesterday,2019-01-24 05:04:00-05:00,LXRX,neutral
788870.0,52 Biggest Movers From Friday,2019-01-22 05:08:00-05:00,LXRX,neutral
788871.0,36 Stocks Moving In Friday's Mid-Day Session,2019-01-18 12:30:00-05:00,LXRX,neutral
788872.0,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",2019-01-18 07:49:00-05:00,LXRX,neutral
788873.0,Sanofi and Lexicon's Oral Type 1 Diabetes Drug Gets an Evenly Split FDA Advisory Panel at 8 to 8,2019-01-17 16:23:00-05:00,LXRX,neutral
788874.0,"The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US",2019-01-17 08:06:00-05:00,LXRX,positive
788875.0,Lexicon Pharmaceuticals Reports FDA Advisory Committee Will Meet Today At 8:00 a.m. ET To Review Sotagliflozin New Drug Application For Treatment Of Type 1 Diabetes,2019-01-17 07:06:00-05:00,LXRX,neutral
788876.0,"Lexicon Pharmaceuticals Shares Halted, News Pending",2019-01-17 07:00:00-05:00,LXRX,positive
788877.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-01-13 15:50:00-05:00,LXRX,neutral
788878.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2018-12-31 09:00:00-05:00,LXRX,neutral
788879.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,LXRX,neutral
788880.0,Lexicon Pharma Reports Topline Phase 1 Results For LX2761 In Diabetes,2018-12-20 07:17:00-05:00,LXRX,neutral
788881.0,"Lexicon Pharmaceuticals Announces Topline Clinical Data For LX9211; Data Shows LX9211 Was Well Tolerated And Met Primary Objectives, Demonstrating A 'Favorable' Safety And Tolerability Profile",2018-12-18 07:09:00-05:00,LXRX,positive
788882.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,LXRX,negative
788883.0,Lexicon Pharmaceuticals Reports FDA Advisory Committee To Review Investigational Sotagliflozin As Potential Treatment For Type 1 Diabetes,2018-11-29 09:03:00-05:00,LXRX,neutral
788884.0,"Lexicon Pharma Reports FDA AdCom Panel Will Review Investigational Sotagliflozin As Potential Treatment For Type-1 Diabetes On Jan. 17, 2019",2018-11-29 09:01:00-05:00,LXRX,neutral
788885.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,LXRX,negative
788886.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,LXRX,negative
788887.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,LXRX,negative
788888.0,"Lexicon Pharmaceuticals, Inc. Q3 EPS $(0.26) Up From $(0.29) YoY, Sales $6.856M Down From $26.942M YoY",2018-11-01 07:49:00-04:00,LXRX,neutral
788889.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,LXRX,negative
788890.0,Lexicon Pharmaceuticals And Ipsen Biopharmaceuticals Announce Health Canada Approval Af XERMELO For Treatment Of Refractory Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy,2018-10-16 08:02:00-04:00,LXRX,positive
788891.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-23 16:10:00-04:00,LXRX,neutral
788892.0,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-09-16 14:22:00-04:00,LXRX,neutral
788893.0,"Lexicon Pharmaceuticals Q2 EPS $(0.33) Beats $(0.34) Estimate, Sales $13.75M Miss $15.86M Estimate",2018-07-30 07:04:00-04:00,LXRX,negative
788894.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,LXRX,neutral
788895.0,"Insider Buys Of The Week: AbbVie, Energen, NuStar And More",2018-07-01 17:14:00-04:00,LXRX,neutral
788896.0,"Insider Buys Of The Week: DDR, Salesforce, Lexicon Pharma",2018-06-25 07:45:00-04:00,LXRX,neutral
788897.0,"Lexicon Pharmaceuticals Announces Positive 52-Week Results from Sotagliflozin inTandem1 Study Presented at #ADA2018, Published in Diabetes Care",2018-06-24 19:46:00-04:00,LXRX,positive
788898.0,Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care,2018-06-23 15:26:00-04:00,LXRX,positive
788899.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,LXRX,neutral
788900.0,"Lexicon Pharma Shares Spike 3% Over Last Few Mins.; Wedbush Issued Mid-Day Note Raising Price Target On Stock From $40 To $42, Maintains Outperform Rating",2018-05-22 14:21:00-04:00,LXRX,positive
788901.0,"Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss",2018-05-03 08:31:00-04:00,LXRX,negative
788902.0,"Lexicon Pharmaceuticals Q1 EPS $(0.40) Beats $(0.43) Estimate, Sales $25.21 Miss $22.96M Estimate",2018-05-03 07:09:00-04:00,LXRX,negative
788903.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,LXRX,neutral
788904.0,Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for Sotagliflozin to Treat Adults With Type 1 Diabetes,2018-03-29 04:05:00-04:00,LXRX,positive
788905.0,17 Stocks Moving In Monday's Pre-Market Session,2018-03-26 08:06:00-04:00,LXRX,neutral
788906.0,Lexicon Pharmaceuticals Announces Regulatory Submissions to the FDA and European Medicines Agency for Sotagliflozin to Treat Adults With Type 1 Diabetes,2018-03-26 07:23:00-04:00,LXRX,positive
788907.0,"Earlier Today, Needham Downgraded Lexicon From Buy to Hold",2018-02-23 12:18:00-05:00,LXRX,neutral
788908.0,"Lexicon Pharma Reports Q4 GAAP EPS $(0.27) vs $(0.31) In Same Qtr. Last Year, Sales $33M vs $30M Est.",2018-02-22 07:14:00-05:00,LXRX,neutral
788909.0,42 Biggest Movers From Yesterday,2018-02-15 04:43:00-05:00,LXRX,neutral
788910.0,36 Stocks Moving In Wednesday's Mid-Day Session,2018-02-14 12:52:00-05:00,LXRX,neutral
788911.0,"Benzinga's Top Upgrades, Downgrades For February 14, 2018",2018-02-14 09:32:00-05:00,LXRX,positive
788912.0,JP Morgan Downgrades Lexicon Pharmaceuticals to Underweight,2018-02-14 08:19:00-05:00,LXRX,positive
788913.0,Lexicon Pharmaceuticals Secures up to $200M Non-Dilutive Term Loan Financing,2017-12-05 04:08:00-05:00,LXRX,positive
788914.0,Lexicon Pharma Option Alert: Jan 19 $15 Puts Sweep (9) at the Ask: 500 @ $4.701 vs 802 OI; Ref=$10.24,2017-11-16 12:55:00-05:00,LXRX,positive
788915.0,"Lexicon Pharmaceuticals Reports Q3 EPS $(0.29) vs $(0.36) Est., Sales $26.94M vs $27.96M Est.",2017-11-08 07:05:00-05:00,LXRX,neutral
788916.0,Lexicon Pharma Reports European Commission Approved XERMELO For Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy,2017-09-19 12:37:00-04:00,LXRX,positive
788917.0,12 Biggest Mid-Day Losers For Thursday,2017-09-14 13:01:00-04:00,LXRX,negative
788918.0,UPDATE: Lexicon Pharma Says 'Patients on sotagliflozin 400 mg spent 2.8 hours longer in target glucose range per day than placebo',2017-09-08 07:06:00-04:00,LXRX,neutral
788919.0,"Lexicon Pharma Offers Pooled Continuous Glucose Monitoring Data From Phase 3 inTandem1, inTandem2 Studies Of Sotagliflozin: Patients On 200mg Spent 1.3 Hours Longer In Target Glucose Range vs Placebo",2017-09-08 07:06:00-04:00,LXRX,neutral
788920.0,Lexicon Pharma Announces Phase 3 Tandem2 Study of Sotagliflozin Met All Secondary Endpoints,2017-08-15 07:02:00-04:00,LXRX,neutral
788921.0,"Lexicon Pharmaceuticals Reports Q2 EPS $(0.33) vs $(0.44), Sales $12.05M vs $18.3M Est.",2017-08-01 07:09:00-04:00,LXRX,neutral
788922.0,Lexicon Pharma Receives Positive Opinion for Xermelo from the EU Medicines Agency,2017-07-21 07:28:00-04:00,LXRX,positive
788923.0,Benzinga's Option Alert Recap From July 12,2017-07-12 16:18:00-04:00,LXRX,positive
788924.0,Lexicon Pharma Option Alert: Aug 18 $15 Puts Sweep (19) at the Bid: 512 @ $0.853 vs 226 OI; Ref=$15.82,2017-07-12 12:58:00-04:00,LXRX,positive
788925.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-06-23 04:07:00-04:00,LXRX,positive
788926.0,Benzinga's Option Alert Recap From June 22,2017-06-22 16:11:00-04:00,LXRX,positive
788927.0,Option Alert: Lexicon Pharma Aug 20.0 Calls Sweep: 602 @  Above Ask!  $1.095: 2716 traded vs 104 OI:  Earnings 8/3 After Close (est)  $17.25 Ref,2017-06-22 15:42:00-04:00,LXRX,positive
788928.0,Lexicon Pharma's XERMELO Included as a Recommended Treatment Option in the National Comprehensive Cancer Network Guidelines,2017-06-19 07:04:00-04:00,LXRX,negative
788930.0,"Lexicon Announces Sotagliflozin Data from Pivotal in Tandem1, Tandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017",2017-06-11 11:07:00-04:00,LXRX,neutral
788931.0,15 Biggest Mid-Day Gainers For Friday,2017-06-09 12:38:00-04:00,LXRX,neutral
788932.0,20 Stocks Moving In Friday's Pre-Market Session,2017-06-09 08:03:00-04:00,LXRX,neutral
788933.0,Lexicon Pharma Shares Resume Trading,2017-06-09 07:30:00-04:00,LXRX,positive
788934.0,Lexicon Pharmaceuticals to Resume at 7:30 AM ET,2017-06-09 07:07:00-04:00,LXRX,neutral
788935.0,Lexicon Pharmaceuticals Reports 'Positive' TLexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study Fop-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes,2017-06-09 07:03:00-04:00,LXRX,positive
788936.0,"Lexicon Pharma Halted, News Pending",2017-06-09 06:56:00-04:00,LXRX,neutral
788937.0,Watch These 5 Huge Call Purchases In Thursday Trade,2017-06-08 04:24:00-04:00,LXRX,positive
788938.0,Option Alert: Lexicon Pharma Jul 15.0 Calls: 3000 @  ASK  $1.45: 3000 traded vs 2420 OI:  Earnings 8/3 After Close (est)  $14.91 Ref,2017-06-07 09:52:00-04:00,LXRX,positive
788939.0,Lexicon Pharma Spikes to High of $15.48 on Volume; June $15 Calls Active,2017-06-02 15:31:00-04:00,LXRX,positive
788940.0,Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin,2017-05-11 06:31:00-04:00,LXRX,positive
788941.0,"Lexicon Pharmaceuticals Reports Q1 EPS $(0.33) vs $(0.42) Est., Sales $18.29M vs $17.7M Est.",2017-05-02 16:47:00-04:00,LXRX,neutral
788942.0,15 Biggest Mid-Day Gainers For Friday,2017-03-03 12:46:00-05:00,LXRX,neutral
788943.0,Mid-Morning Market Update: Markets Edge Lower; Big Lots Profit Beats Estimates,2017-03-03 10:01:00-05:00,LXRX,positive
788944.0,22 Stocks Moving In Friday's Pre-Market Session,2017-03-03 08:28:00-05:00,LXRX,neutral
788945.0,"Lexicon Pharma Reports Q4 EPS $(0.31) vs $(0.52) Est., $0.76 in Same Qtr. Last Year, Sales $23M vs $15.6M Est.",2017-03-03 07:03:00-05:00,LXRX,neutral
788946.0,"Earnings Scheduled For March 3, 2017",2017-03-03 05:05:00-05:00,LXRX,neutral
788947.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-03-01 08:19:00-05:00,LXRX,neutral
788948.0,UPDATE: Lexicon Reports Xermelo Treatment Now Available by Prescription And Will Be In Select Specialty Pharmacies Beginning March 6th,2017-02-28 15:57:00-05:00,LXRX,neutral
788949.0,FDA Approves Lexicon Drug XERMELO,2017-02-28 15:57:00-05:00,LXRX,positive
788950.0,Lexicon Pharma Shares Halted News Pending,2017-02-28 15:43:00-05:00,LXRX,positive
788951.0,"Reminder: Lexicon Pharmaceuticals Telotristate Etiprate Under FDA Priority Review, PDUFA Date Tuesday, Feb. 28th",2017-02-27 15:20:00-05:00,LXRX,neutral
788952.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,LXRX,neutral
788953.0,FDA Watch: February's Notable PDUFA Dates,2017-02-06 14:42:00-05:00,LXRX,neutral
788954.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,LXRX,neutral
788955.0,15 Biggest Mid-Day Losers For Wednesday,2016-12-21 13:05:00-05:00,LXRX,negative
788956.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-21 08:25:00-05:00,LXRX,neutral
788957.0,Lexicon Phase 3 Trial for Sotagliflozin Met Primary Endpoint,2016-12-21 06:47:00-05:00,LXRX,neutral
788958.0,18 Stocks Moving In Tuesday's Pre-Market Session,2016-12-06 08:25:00-05:00,LXRX,neutral
788959.0,Lexicon Pharmaceuticals Down 16.2% After Hours On Disappointing Phase 2 Results,2016-12-05 16:09:00-05:00,LXRX,negative
788960.0,Lexicon Top-Line Phase 2 Results Not Shown To Be Statistically Significant,2016-12-05 16:02:00-05:00,LXRX,positive
788961.0,Mid-Morning Market Update: Markets Rise; Donald Trump Wins 2016 Presidential Election,2016-11-09 09:54:00-05:00,LXRX,positive
788962.0,Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb,2016-11-07 07:07:00-05:00,LXRX,negative
788963.0,"Lexicon Pharmaceuticals, Inc. Shares Up ~7% Following Earlier Q3 Report: EPS $(0.35) vs Est $(0.49), Revenue $27.72M vs Est 9.68M",2016-11-01 10:48:00-04:00,LXRX,positive
788964.0,Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes,2016-10-25 06:59:00-04:00,LXRX,positive
788965.0,Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects',2016-10-07 10:45:00-04:00,LXRX,positive
788966.0,"H.C. Wainwright Initiates Coverage on Lexicon Pharmaceuticals at Buy, Announces $26.00 PT",2016-10-07 07:27:00-04:00,LXRX,neutral
788967.0,"Lexicon Pharmaceuticals Reports Agreement To Buy Out Remaining Obligations To Symphony Icon For $21.01M, Buyout To Replace Remaining Contingent Payments Of Up To $29.55M",2016-10-05 07:06:00-04:00,LXRX,positive
788968.0,Option Alert: LXRX Jan 20 $17.5 Puts at the bid: Volume of 500 @ 2.05 vs 49 Open Interest,2016-09-21 12:08:00-04:00,LXRX,positive
788969.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-15 08:27:00-04:00,LXRX,neutral
788970.0,"UPDATE: Lexicon Pharma Says PDUFA Date for Telotristat Extended from Nov. 30, 2016 to Feb. 28, 2017",2016-09-14 17:48:00-04:00,LXRX,neutral
788971.0,Lexicon Pharma Reports Extension of PDUFA Date for Telotristat Etiprate for Treatment of Carinoid Syndrome,2016-09-14 17:47:00-04:00,LXRX,neutral
788972.0,10 Stocks Which Rallied Three Days,2016-09-12 06:31:00-04:00,LXRX,neutral
788973.0,Mid-Day Market Update: Dow Down Over 200 Points; Finisar Shares Surge Following Strong Results,2016-09-09 11:53:00-04:00,LXRX,positive
788974.0,Benzinga's Volume Movers,2016-09-09 11:19:00-04:00,LXRX,neutral
788975.0,Stocks Hitting 52-Week Highs,2016-09-09 11:10:00-04:00,LXRX,neutral
788976.0,Mid-Morning Market Update: Markets Open Lower; Kroger Lowers FY Forecast,2016-09-09 10:06:00-04:00,LXRX,negative
788977.0,12 Stocks Moving In Friday's Pre-Market Session,2016-09-09 08:29:00-04:00,LXRX,neutral
788978.0,Lexicon Announces First Successful Phase 3 Trial of an Oral Anti-diabetic for Type 1 Diabetes,2016-09-09 07:00:00-04:00,LXRX,positive
788979.0,Lexicon Pharmaceuticals Reports Q2 $(0.37) vs. Est. $(0.40),2016-08-04 07:32:00-04:00,LXRX,neutral
788980.0,Buy/High Risk Rating Given To Lexicon Pharmaceuticals By Citi Analysts,2016-08-02 10:40:00-04:00,LXRX,negative
788981.0,"Citigroup Initiates Coverage on Lexicon Pharmaceuticals at Buy, Announces $21.00 PT",2016-08-02 05:58:00-04:00,LXRX,neutral
788982.0,Lexicon Announces Validation Of Marketing Authorization For Carcinoid Syndrome Treatment,2016-07-18 16:05:00-04:00,LXRX,neutral
788983.0,Lexicon Reports FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome,2016-05-31 08:03:00-04:00,LXRX,neutral
788984.0,Cowen & Company Assumes Lexicon Pharmaceuticals at Market Perform,2016-05-05 17:45:00-04:00,LXRX,neutral
788985.0,"Lexicon Pharmaceuticals Reports Q1 EPS $(0.34) vs. Est. $(0.30), Rev. $12.5M vs. Est. $11.11M",2016-05-03 07:08:00-04:00,LXRX,neutral
788986.0,Lexicon Submits NDA To FDA For Telotristat Etiprate For Carcinoid Syndrome Treatment,2016-03-30 17:03:00-04:00,LXRX,neutral
788987.0,"Lexicon Pharma Reports Q4 EPS $0.76, Rev. $127.28M",2016-03-01 07:04:00-05:00,LXRX,neutral
788988.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,LXRX,neutral
788989.0,"Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial, Met Primary Endpoint",2015-12-01 08:08:00-05:00,LXRX,positive
788990.0,Mid-Morning Market Update: Markets Decline; Humana Earnings Beat Estimates,2015-11-06 10:03:00-05:00,LXRX,neutral
788991.0,Morning Market Gainers,2015-11-06 09:43:00-05:00,LXRX,neutral
788992.0,Laxicon Pharma Report Q3 Loss $0.34 Vs Est Loss $0.36,2015-11-06 06:01:00-05:00,LXRX,negative
788993.0,"Sanofi, Lexicon to Collaborate on Sotagliflozin, a Potential Diabetes Treatment",2015-11-06 04:21:00-05:00,LXRX,neutral
788994.0,Option Alert: $LXRX Apr $7.5 Put; 2500 Contracts @$2.40; Now $9.60,2015-10-28 15:06:00-04:00,LXRX,positive
788995.0,"Wedbush's Moussatos Reiterates Outperform, $19 Target on Lexicon Pharma as 'TELESTAR Patient Exit Interviews Suggests A Meaningful Improvement in Quality of Life...'",2015-10-19 16:30:00-04:00,LXRX,positive
788996.0,Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being,2015-10-19 07:03:00-04:00,LXRX,negative
788997.0,Lexicon Announces Telotristat Etiprate Data To Be Presented At North American Neuroendocrine Tumor Society Annual Symposium,2015-10-09 08:01:00-04:00,LXRX,negative
788998.0,"US Stock Futures Rise Ahead Of Housing, Consumer Confidence Data",2015-09-29 07:10:00-04:00,LXRX,positive
788999.0,Lexicon's Telotristat Etiprate Shows Clinical Benefit In Treating Carcinoid Syndrome In Cancer Patients When Added To Standard Of Care,2015-09-29 06:03:00-04:00,LXRX,positive
789000.0,Tuesday's After-Hours Movers: 10 Stocks Moving After The Bell,2015-09-23 07:19:00-04:00,LXRX,neutral
789001.0,Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress,2015-08-26 08:02:00-04:00,LXRX,negative
789002.0,Benzinga's Top Downgrades,2015-08-10 09:34:00-04:00,LXRX,positive
789003.0,"JP Morgan Downgrades Lexicon Pharmaceuticals to Neutral, Raises PT to $14.00",2015-08-10 07:25:00-04:00,LXRX,positive
789004.0,Lexicon Pharma Pipeline Progress Comments,2015-08-07 07:04:00-04:00,LXRX,positive
789005.0,Lexicon Pharma Reports Q2 EPS $(0.27) vs. Est. $(0.32),2015-08-07 07:04:00-04:00,LXRX,neutral
789006.0,Mid-Morning Market Update: Markets Edge Higher; Coach Beats Q4 Expectations,2015-08-04 10:30:00-04:00,LXRX,neutral
789007.0,Mid-Day Market Update: Monday's Top 10 Volume Stocks,2015-08-03 13:33:00-04:00,LXRX,positive
789008.0,"Mid-Day Market Update: Monday's Movers, Greece's Stock Market Opens, Auto Sales Boom And More",2015-08-03 13:28:00-04:00,LXRX,neutral
789009.0,Lexicon Pharma Shares Now Up 60+% to Over $13.50 Following Earlier News TELESTAR Trial Met Primary Endpoint,2015-08-03 12:47:00-04:00,LXRX,positive
789010.0,Hearing Wedbush Raises PT on Lexicon to $19,2015-08-03 10:42:00-04:00,LXRX,neutral
789011.0,Benzinga's Volume Movers,2015-08-03 10:24:00-04:00,LXRX,neutral
789012.0,Stocks Hitting 52-Week Highs,2015-08-03 10:07:00-04:00,LXRX,neutral
789013.0,Morning Market Gainers,2015-08-03 09:37:00-04:00,LXRX,neutral
789014.0,Benzinga's Top #PreMarket Gainers,2015-08-03 08:19:00-04:00,LXRX,positive
789015.0,US Stock Futures Flat Ahead Of Economic Data,2015-08-03 07:17:00-04:00,LXRX,neutral
789016.0,Lexicon Pharmaceuticals +14% Premarket as TELESTAR Phase 3 Clinical Trial Met Primary Endpoint,2015-08-03 06:50:00-04:00,LXRX,neutral
789017.0,Lexicon Pharmaceuticals Announces Pivotal TELESTAR Phase 3 Clinical Trial Met Primary Endpoint,2015-08-03 04:25:00-04:00,LXRX,neutral
789018.0,Mid-Afternoon Market Update: Dow Dips Over 100 Points; Crude Oil Tumbles 5.5%,2015-07-06 14:52:00-04:00,LXRX,negative
789019.0,Lexicon Presents Sotagliflozin Manuscript at American Diabetes Association Diabetes Care Symposium,2015-06-07 08:15:00-04:00,LXRX,positive
789020.0,"Lexicon Pharma Reports Q1 Loss of $0.04/Share, Inline, Sales $1.8M vs $1.1M Est.",2015-04-29 16:17:00-04:00,LXRX,negative
789021.0,Lexicon Reports One For Seven Reverse Stock Split,2015-04-29 16:02:00-04:00,LXRX,neutral
789022.0,Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research,2015-04-20 08:38:00-04:00,LXRX,neutral
789023.0,"Lexicon Pharma, Bristol-Myers Squibb  Choose Development Candidate for Neuropathic Pain in Neuroscience Drug Discovery and Development Alliance",2015-04-15 07:02:00-04:00,LXRX,negative
789024.0,Jefferies: 10 Buyout Targets To Own During The M&A Boom,2015-04-13 16:17:00-04:00,LXRX,neutral
789025.0,Lexicon Pharmaceuticals Announces First Patient Screened In Crucial Phase 3 Clinical Trial Of Sotagliflozin,2015-03-25 08:06:00-04:00,LXRX,neutral
789026.0,"Lexicon, Ipsen Expand Licensing & Commercialization Agreement For Telotristat Etiprate To Canada",2015-03-18 08:32:00-04:00,LXRX,positive
789027.0,Lexicon Pharma Announces Closing of Enrollment in Pivotal Phase 3 Clinical Trial of Telotristat Etiprate,2015-03-09 08:07:00-04:00,LXRX,neutral
789028.0,Morning Market Gainers,2015-03-04 09:46:00-05:00,LXRX,neutral
789029.0,UPDATE: Lexicon Pharmaceuticals Shares Surge On Upbeat Q4 Results,2015-03-04 09:20:00-05:00,LXRX,positive
789030.0,"Lexicon Pharma Q4 EPS $0.00 vs -$0.03, Revenue $21.5M vs $12M",2015-03-04 07:02:00-05:00,LXRX,neutral
789031.0,"Earnings Scheduled For March 4, 2015",2015-03-04 05:09:00-05:00,LXRX,neutral
789032.0,"Lexicon's VP, Chief Scientific Officer Brian Zambrowicz Leaves Company",2015-02-23 16:32:00-05:00,LXRX,neutral
789033.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,LXRX,neutral
789034.0,Stocks Hitting 52-Week Lows,2014-11-21 10:01:00-05:00,LXRX,negative
789035.0,US Stock Futures Rise Ahead Of Earnings,2014-11-21 07:35:00-05:00,LXRX,neutral
789036.0,Lexicon Prices 49.751M Share Offering @$1.005/Share,2014-11-21 05:00:00-05:00,LXRX,positive
789037.0,Mid-Afternoon Market Update: Best Buy Rises After Upbeat Results; GoPro Shares Slide,2014-11-20 14:48:00-05:00,LXRX,positive
789038.0,"Mid-Day Losers From November 20: Lexicon Pharmaceuticals, GoPro, Donaldson Company, Keurig Green Mountain",2014-11-20 13:09:00-05:00,LXRX,negative
789039.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Williams-Sonoma Shares Climb On Earnings Beat,2014-11-20 12:38:00-05:00,LXRX,positive
789040.0,Mid-Morning Market Update: Markets Mixed; Dollar Tree Posts Upbeat Earnings,2014-11-20 11:28:00-05:00,LXRX,neutral
789041.0,Morning Market Losers,2014-11-20 09:49:00-05:00,LXRX,negative
789042.0,Lexicon Announces $75M Proposed Convertible Senior Notes Offering,2014-11-19 16:04:00-05:00,LXRX,neutral
789043.0,Lexicon Announces Proposed Common Stock Offering Of $50M In Shares,2014-11-19 16:02:00-05:00,LXRX,positive
789044.0,"Stifel Nicolaus Maintains Buy on Lexicon Pharmaceuticals, Inc., Lowers PT to $3.50",2014-11-05 07:08:00-05:00,LXRX,negative
789045.0,"Lexicon Pharmaceuticals, Inc. Reports Q3 EPS of $(0.08) Which May Not Compare $(0.05) Est; Revenue of $400.0K Which May Not Compare $140.0K Est",2014-11-04 16:10:00-05:00,LXRX,neutral
789046.0,"Lexicon, Ipsen Enter Ex-North America/Japan Licensing and Commercialization Agreement for Telotristat Etiprate ",2014-10-22 05:02:00-04:00,LXRX,positive
789047.0,Nurix Appoints Arthur Sands As CEO,2014-09-18 08:28:00-04:00,LXRX,neutral
789048.0,Lexicon Pharmaceuticals Spikes Higher After-Hours,2014-09-11 16:38:00-04:00,LXRX,neutral
789049.0,"Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care",2014-09-11 16:32:00-04:00,LXRX,positive
789050.0,S-3 from Lexicon Pharma Shows Registration for $150M Mixed Securities Shelf Offering,2014-08-29 16:17:00-04:00,LXRX,positive
789051.0,Benzinga's Top Downgrades,2014-08-19 09:00:00-04:00,LXRX,positive
789052.0,Gabelli Downgrades Lexicon Pharmaceuticals To Hold,2014-08-19 08:43:00-04:00,LXRX,neutral
789053.0,"Gabelli Downgrades Lexicon Pharmaceuticals, Inc. to Hold",2014-08-19 06:40:00-04:00,LXRX,neutral
789054.0,"Lexicon Pharmaceuticals, Inc. Reports Q2 EPS of $(0.05), Inline",2014-08-07 07:06:00-04:00,LXRX,neutral
789055.0,FOMC To End QE In October; The Container Store Shares Slide,2014-07-09 15:05:00-04:00,LXRX,positive
789056.0,AeroVironment Surges On Upbeat Results; The Container Store Shares Slide,2014-07-09 12:27:00-04:00,LXRX,positive
789057.0,Markets Edge Higher; Alcoa Profit Beats Street View,2014-07-09 10:20:00-04:00,LXRX,positive
789058.0,Morning Market Movers ,2014-07-09 09:42:00-04:00,LXRX,neutral
789059.0,US Stock Futures Flat; All Eyes On Fed Minutes,2014-07-09 07:40:00-04:00,LXRX,neutral
789060.0,Lexicon And JDRF Collaborate For Phase 2 Clinical Trial Of LX4211 In Type 1 Diabetes,2014-07-09 07:03:00-04:00,LXRX,neutral
789061.0,Lexicon Announces Lonnel Coats President and CEO,2014-07-07 16:15:00-04:00,LXRX,neutral
789062.0,3 Small-Cap Biotechs That Institutions Are Loving,2014-07-07 14:54:00-04:00,LXRX,positive
789063.0,Lexicon Pharmaceuticals Reports Q1 EPS of $(0.06) vs $(0.05) Est; Revenue of $300.0K vs $120.0K Est,2014-05-08 06:19:00-04:00,LXRX,neutral
789064.0,Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat Estimates,2014-04-14 10:17:00-04:00,LXRX,neutral
789065.0,Morning Market Movers ,2014-04-14 09:38:00-04:00,LXRX,neutral
789066.0,US Stock Futures Flat; Citigroup Earnings In Focus,2014-04-14 07:43:00-04:00,LXRX,neutral
789067.0,Lexicon Pharmaceuticals Announces LX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial ,2014-04-14 06:03:00-04:00,LXRX,positive
789068.0,Lexicon Pharma Shares Up ~1.2% Following 1.72M Share Block Trade at $1.70/Share,2013-12-17 10:55:00-05:00,LXRX,positive
789069.0,Benzinga's Top Initiations,2013-12-06 08:14:00-05:00,LXRX,positive
789070.0,"UPDATE: Bank of America Initiates Underperform On Lexicon Pharmaceuticals, Says Asset Overvalued",2013-12-06 07:19:00-05:00,LXRX,positive
789071.0,"Bank of America Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Underperform, Announces $1.50 PO",2013-12-06 06:38:00-05:00,LXRX,negative
789072.0,Benzinga's Top #PreMarket Losers,2013-12-03 08:43:00-05:00,LXRX,negative
789073.0,US Stock Futures Signal Lower Start On Wall Street,2013-12-03 07:03:00-05:00,LXRX,negative
789074.0,Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo and LX1033 were Not Statistically Significant,2013-12-03 06:07:00-05:00,LXRX,negative
789075.0,"Stocks to Watch for November 25, 2013",2013-11-25 11:35:00-05:00,LXRX,neutral
789076.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2013-10-22 04:29:00-04:00,LXRX,negative
789077.0,Wedbush's Moussatos Says Sees No 'Major Impact' Following News of Lower-Than-Expected Benefit from Pilot Study,2013-10-09 12:06:00-04:00,LXRX,positive
789078.0,Benzinga's Top Pre-Market Losers,2013-10-09 08:20:00-04:00,LXRX,negative
789079.0,"Lexicon Pilot Study of Telotristat Etiprate In Ulcerative Colitis Achieves Primary Objective Demonstrating Safety, Tolerabilty",2013-10-09 06:05:00-04:00,LXRX,positive
789080.0,"Market Wrap For Tuesday, October 1: Government Down, Markets Up",2013-10-01 16:36:00-04:00,LXRX,neutral
789081.0,Mid-Afternoon Market Update: Markets Remain Up As Government Shutdown Continues,2013-10-01 15:17:00-04:00,LXRX,neutral
789082.0,Mid-Day Market Update: US Stocks Extend Gains; Lexicon Shares Surge,2013-10-01 13:24:00-04:00,LXRX,positive
789083.0,Mid-Morning Market Update: Markets Rise; Walgreen Earnings Surge 86%,2013-10-01 10:48:00-04:00,LXRX,neutral
789084.0,Morning Market Movers ,2013-10-01 09:47:00-04:00,LXRX,neutral
789085.0,Benzinga's Top Pre-Market Gainers,2013-10-01 08:39:00-04:00,LXRX,positive
789086.0,"Lexicon Pharma Reports Results from Trial of LX4211, Says Met Primary Goal, Says There Were No Serious Adverse Events",2013-10-01 06:48:00-04:00,LXRX,negative
789087.0,"Lexicon Pharmaceuticals, Inc. Reports Q2 EPS of $(0.06) vs $(0.05) Est; Revenue of $214.0K vs $280.0K Est",2013-07-30 06:25:00-04:00,LXRX,neutral
789088.0,Lexicon Pharmaceuticals Provides Clinical Pipeline Update ,2013-07-30 06:24:00-04:00,LXRX,neutral
789089.0,"Market Wrap for Tuesday, July 23: Stocks Close Mixed as Investors Focus on Earnings ",2013-07-23 16:19:00-04:00,LXRX,neutral
789090.0,Lexicon Pharma Issues Preclincial Data on LX2761,2013-06-24 08:06:00-04:00,LXRX,neutral
789091.0,UPDATE: Morgan Stanley Downgrades Lexicon Pharmaceuticals on Challenged Valuation,2013-06-11 08:25:00-04:00,LXRX,negative
789092.0,"Morgan Stanley Downgrades Lexicon Pharmaceuticals, Inc. to Underweight, Lowers PT to $1.50",2013-06-11 06:26:00-04:00,LXRX,negative
789093.0,UPDATE: Jefferies Initiates Lexicon Pharmaceuticals at Buy on Class-Leading SGLT Inhibitor,2013-05-30 09:15:00-04:00,LXRX,negative
789094.0,"Jefferies Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Buy, Announces $3.50 PT",2013-05-30 06:38:00-04:00,LXRX,neutral
789095.0,"Jefferies Initiates Coverage on Lexicon Pharmaceuticals, Inc. at Buy, Announces $3.50 PT",2013-05-29 16:26:00-04:00,LXRX,neutral
789096.0,"Lexicon Pharmaceuticals, Inc. Reports Q1 EPS of $(0.05), Inline; Revenue of $400.0K vs $300.0K Est",2013-05-10 06:15:00-04:00,LXRX,neutral
789097.0,Lexicon Issues Update on Phase 2 Trial of LX4211 In Type 1 Diabetes  ,2013-05-10 06:10:00-04:00,LXRX,neutral
789098.0,"Market Wrap for Monday, April 29: Stocks Start Week With a Rally",2013-04-29 16:12:00-04:00,LXRX,neutral
789099.0,Stocks Surge as Fiscal Cliff Deal Appears Close ,2012-12-31 16:46:00-05:00,LXRX,neutral
789100.0,"Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise",2012-12-31 13:10:00-05:00,LXRX,negative
789101.0,"Mid-Morning Market Update: Markets Rise Ahead of Fiscal Cliff, Cott Falls",2012-12-31 10:47:00-05:00,LXRX,neutral
789102.0,Mid-Morning Market Update: Caribou Bought Out; Clearwire Plummets,2012-12-17 11:31:00-05:00,LXRX,neutral
789103.0,Benzinga's Top Pre-Market Gainers,2012-12-17 08:21:00-05:00,LXRX,positive
789104.0,Lexicon Pharma Shares Rise Following FDA Fast Track Designation for LX1033 for IBS,2012-12-17 07:50:00-05:00,LXRX,positive
789105.0,Lexicon Pharma Says Primary Efficacy Endpoint Was Achieved,2012-11-06 10:34:00-05:00,LXRX,neutral
789106.0,From Earlier: Lexicon Pharmaceuticals Reports Q3 EPS $-0.06 vs $-0.06 Est; Revenues $372K vs $600.00K Est,2012-11-06 09:09:00-05:00,LXRX,neutral
789107.0,Lexicon Prices 17.5M Shares At $2.25 per Share,2012-10-18 09:27:00-04:00,LXRX,positive
789108.0,Lexicon Announces Proposed Common Stock Offering,2012-10-17 16:14:00-04:00,LXRX,neutral
789109.0,Benzinga's Top Pre-Market Gainers,2012-10-16 08:15:00-04:00,LXRX,positive
789110.0,Benzinga's Top Pre-Market Gainers,2012-10-12 08:15:00-04:00,LXRX,positive
789111.0,A Peek Into The Market Before The Trading Starts,2012-10-12 07:16:00-04:00,LXRX,neutral
789112.0,Lexicon Pharmaceuticals Announces Phase 2 Trial Of Telotristat Etiprate Shows Positive Results In Carcinoid Syndrome ,2012-10-12 06:30:00-04:00,LXRX,positive
789113.0,Gabelli & Company Initiates Coverage on Lexicon Pharmaceuticals at Buy,2012-09-13 08:53:00-04:00,LXRX,neutral
789114.0,A Peek Into The Market Before The Trading Starts,2012-08-16 07:19:00-04:00,LXRX,neutral
789115.0,Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies,2012-08-16 06:07:00-04:00,LXRX,neutral
789116.0,Benzinga's Top Pre-Market Gainers,2012-08-06 08:09:00-04:00,LXRX,positive
789117.0,Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results ,2012-07-31 06:37:00-04:00,LXRX,neutral
789118.0,A Peek Into The Market Before The Trading Starts,2012-06-29 07:21:00-04:00,LXRX,neutral
789119.0,Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics ,2012-06-29 06:36:00-04:00,LXRX,neutral
789120.0,Lexicon Pharmaceuticals Soaring After Stifel Nicolaus Raises Price Target ,2012-06-26 12:30:00-04:00,LXRX,neutral
789121.0,UPDATE: Stifel Nicolaus Raises PT to $4 on Lexicon Pharmaceuticals on LX4211 P2b Efficacy Data  ,2012-06-26 09:00:00-04:00,LXRX,neutral
789122.0,"Stifel Nicolaus Maintains Lexicon Pharmaceuticals at Buy, Raises PT from $3 to $4",2012-06-26 07:41:00-04:00,LXRX,neutral
789123.0,Benzinga's Top Pre-Market Gainers,2012-06-25 08:09:00-04:00,LXRX,positive
789124.0,Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes ,2012-06-25 06:55:00-04:00,LXRX,positive
789125.0,Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes ,2012-05-03 07:03:00-04:00,LXRX,neutral
789126.0,LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes ,2012-01-09 16:30:00-05:00,LXRX,negative
789127.0,Investor Ideas' Biotech/ Pharma Stocks To Watch: Friday's Gainers,2011-12-12 11:46:00-05:00,LXRX,neutral
789128.0,A Peek Into The Market Before The Trading Starts,2011-11-22 07:31:00-05:00,LXRX,neutral
789129.0,Lexicon Announces Commencement of Rights Offering to Stockholders ,2011-11-22 06:55:00-05:00,LXRX,neutral
789130.0,Lexicon Pharmaceuticals Announces LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects  ,2011-09-13 07:17:00-04:00,LXRX,positive
789131.0,Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology,2011-08-10 18:26:00-04:00,LXRX,negative
789132.0,"Lexicon Pharmaceuticals Announces Phase 2 Trial of LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome  ",2011-08-09 07:09:00-04:00,LXRX,positive
789133.0,"Phase 2 Trial of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome",2011-08-09 06:15:00-04:00,LXRX,positive
789134.0,Lexicon Pharmaceuticals Crossed Below 200 Day Moving Average Of $1.67,2011-07-08 12:35:00-04:00,LXRX,neutral
789135.0,Lexicon Pharmaceuticals Trading Up Over 9% in Pre-Market,2011-06-24 07:59:00-04:00,LXRX,neutral
789136.0,J.P. Morgan Maintains Overweight Rating on Lexicon Pharmaceuticals,2011-05-13 08:06:00-04:00,LXRX,negative
789137.0,"Benzinga's Top Pre-Market NASDAQ Gainers (CNXT, GENZ, XING, LXRX)",2011-01-10 08:21:00-05:00,LXRX,positive
789138.0,"Morning Market Movers (HAUP, LXRX, ANX, CAFI)",2011-01-06 10:05:00-05:00,LXRX,neutral
789139.0,"Benzinga's Top Pre-Market NASDAQ Gainers (LXRX, ARMH, MVIS, GOLD)",2011-01-06 08:22:00-05:00,LXRX,positive
789140.0,Lexicon Posts Narrower-Than-Expected Q2 Loss,2010-08-09 07:10:00-04:00,LXRX,negative
789141.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,LXRX,positive
789142.0,"Benzinga’s News Roundup (LXRX, MET, AZN, BA)",2010-03-08 07:59:00-05:00,LXRX,neutral
789143.0,"Benzinga’s Top Pre-Market Gainers (LXRX, STKL, STX, PLXS, DEAR, EBAY)",2010-01-21 08:24:00-05:00,LXRX,positive
789144.0,"Benzinga’s Top Pre-Market Gainers (DEER, LXRX, RMBS, SIRI, CREE, AIXG, DDSS)",2010-01-20 08:28:00-05:00,LXRX,positive
789145.0,"Biggest Losers (SPPI, ACOR, LEAP, LXRX, CLRT)",2009-10-09 11:45:00-04:00,LXRX,negative
789146.0,"Stocks to Watch (AA, HOTT, SVNT, SCSC, LXRX, BX)",2009-10-08 07:55:00-04:00,LXRX,neutral
789147.0,"Biggest Losers (AGCO,FNET,LXRX,DSCO,CGA)",2009-09-16 11:57:00-04:00,LXRX,negative
789148.0,"Today's Morning Top Gainers (FNET,LXRX,DIET,CLFD,MPG,CVM)",2009-09-15 12:16:00-04:00,LXRX,positive
789149.0,"New 52-Week High Stocks – LXRX,CLFD,CVM,AAPL,CRUS",2009-09-15 11:42:00-04:00,LXRX,neutral
789150.0,Lexicon Pharmaceuticals (LXRX) Shares Doubles On Positive Early Trials,2009-09-15 10:33:00-04:00,LXRX,positive
